−7JPY
−1.11 BJPY
617.00 MJPY
156.69 M
About SOLASIA PHARMA K K
Sector
CEO
Yoshihiro Arai
Headquarters
Tokyo
Website
Employees (FY)
24
Founded
2006
ISIN
JP3436500007
FIGI
BBG00G21HHJ3
Solasia Pharma KK engages in the development, sale, import and export of pharmaceutical products and medical devices. It provides patients access to western oncology and hematology therapies by developing products licensed from western pharmaceutical and biotechnology companies. The company was founded by Bard Geesaman, John McDonald, and Koji Shinozaki in December 2006 and is headquartered in Tokyo, Japan.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 4597 is 26.00 JPY — it has increased by 4.00% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on TSE exchange SOLASIA PHARMA K K stocks are traded under the ticker 4597.
SOLASIA PHARMA K K is going to release the next earnings report on May 15, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for SOLASIA PHARMA K K has a max estimate of 85.00 JPY and a min estimate of 85.00 JPY.
Yes, you can track SOLASIA PHARMA K K financials in yearly and quarterly reports right on TradingView.
Like other stocks, 4597 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SOLASIA PHARMA K K stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 24.00 employees. See our rating of the largest employees — is SOLASIA PHARMA K K on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SOLASIA PHARMA K K EBITDA is −637.00 M JPY, and current EBITDA margin is −103.57%. See more stats in SOLASIA PHARMA K K financial statements.